Answer
It is unknown whether evolocumab (Repatha) passes into human breast milk; risk to breastfed infants cannot be excluded, so a decision to stop breastfeeding or stop or avoid treatment must weigh breastfeeding benefits for the child against treatment benefits for the woman.
Sources for this answer
- Repatha SureClickAmgen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 21Document updated
Sources checked